New drug combo aims to wipe out hepatitis c in Hard-to-Treat patients
NCT ID NCT07316842
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 30 adults with chronic hepatitis C (genotype 3) and mild to moderate liver fibrosis who are taking ravidasvir and sofosbuvir as part of their regular care. Researchers will check if the virus is undetectable 12 weeks after treatment ends (SVR12). The goal is to see how well this drug combination works in a real-world setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ravidasvir and sofosbuvir
What this could lead to
If successful, this could confirm that the combination of ravidasvir and sofosbuvir effectively clears the hepatitis C virus in people with genotype 3 and mild liver damage.
What could go wrong
This is a small observational study with only 30 participants, so results may not apply to everyone. It is not a randomized trial, and the long-term durability of the response beyond 12 weeks is not assessed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VIRAL HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center of Target Therapy LLC.
Moscow, 125008, Russia